Feb 24, 2026 07:00AM
Dec 21, 2025 04:00AM
Nov 24, 2025 07:02AM
Nov 24, 2025 07:00AM
Nov 5, 2025 07:00AM
Oct 20, 2025 04:15AM
Oct 13, 2025 07:00AM Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
Sep 24, 2025 02:35AM
Sep 19, 2025 04:47AM
Sep 17, 2025 04:31PM
Sep 17, 2025 04:30PM
Aug 8, 2025 04:05PM
Aug 8, 2025 04:05PM
Aug 6, 2025 07:00AM Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jun 11, 2025 08:30AM
Jun 6, 2025 08:38AM
Jun 6, 2025 07:01AM
Jun 6, 2025 07:00AM
May 31, 2025 08:00AM
May 31, 2025 08:00AM
May 1, 2025 07:00AM Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update
Apr 23, 2025 10:45AM
Apr 23, 2025 10:44AM
Apr 9, 2025 09:34AM
Mar 11, 2025 06:46AM
Mar 11, 2025 06:45AM
Feb 11, 2025 07:00AM
Jan 10, 2025 07:08AM Arvinas Inc. (ARVN) Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
Jan 10, 2025 07:00AM
Dec 22, 2024 04:00AM
Dec 10, 2024 09:09AM
Dec 10, 2024 09:05AM
Nov 25, 2024 05:35PM
Oct 30, 2024 07:00AM
Jul 30, 2024 07:00AM Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jul 22, 2024 08:31AM
Jul 22, 2024 08:30AM
Jul 15, 2024 08:00AM
May 23, 2024 05:00PM
May 16, 2024 06:01AM
May 16, 2024 06:00AM
May 9, 2024 04:42PM Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 7, 2024 07:00AM
Feb 27, 2024 07:00AM
Feb 14, 2024 08:00AM
Feb 6, 2024 06:46AM
Feb 6, 2024 06:45AM
Nov 7, 2023 07:00AM
Jul 6, 2023 09:01AM Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
Jul 6, 2023 09:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All